Results 11 to 20 of about 102,854 (205)

BRAF Mutations in Canine Cancers. [PDF]

PLoS ONE, 2015
Activating mutations of the BRAF gene lead to constitutive activation of the MAPK pathway. Although many human cancers carry the mutated BRAF gene, this mutation has not yet been characterized in canine cancers.
Hiroyuki Mochizuki, Katherine Kennedy, Susan G Shapiro, Matthew Breen   +3 more
doaj   +4 more sources

BRAF Mutations in Hairy-Cell Leukemia [PDF]

New England Journal of Medicine, 2011
Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose underlying genetic lesion is still obscure.We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome of leukemic and matched normal cells purified from the peripheral blood of an index patient with HCL.
TIACCI, Enrico, Trifonov V, SCHIAVONI, GIANLUCA, Holmes A, Kern W, MARTELLI, Maria Paola, Pucciarini A, Bigerna B, Pacini R, Wells VA, SPORTOLETTI, PAOLO, PETTIROSSI, Valentina, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, PASQUALUCCI, Laura, Rabadan R, FALINI, Brunangelo   +35 more
openaire   +8 more sources

Clinical prognosis in BRAF-mutated PTC [PDF]

Arquivos Brasileiros de Endocrinologia & Metabologia, 2007
BRAF mutation has recently emerged as a potential prognostic marker for papillary thyroid carcinoma (PTC) due to several studies suggesting that it may condition the development of tumors with aggressive behavior. A study of the phenotypes of thyroid follicular cell lines and transgenic mice characterized by targeted expression of BRAF mutation ...
Puxeddu, Efisio, Moretti, Sonia
openaire   +5 more sources

Frequency and significance of Ras, Tert promoter, and Braf mutations in cytologically indeterminate thyroid nodules: A monocentric case series at a tertiary-level Endocrinology unit [PDF]

, 2017
PurposeThe management of thyroid nodules of indeterminate cytology is controversial. Our study aimed to establish the frequency and significance of H-,K-,N-RAS, TERT promoter, and BRAF gene mutations in thyroid nodes of indeterminate cytology and to ...
Barollo, Susi, Bertazza, Loris, CASAL IDE, Eric, Cavedon, Elisabetta, Censi, Simona, DE LAZZARI, Paola, Fassina, Ambrogio, Galuppini, Francesca, Iacobone, Maurizio, Mian, Caterina, Nacamulli, Davide, Pennelli, Gianmaria, Vianello, Federica, WATUTANTRIGE FERNANDO, Sara   +13 more
core   +2 more sources

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report [PDF]

, 2015
The recent Combi-v [1] and Combi-d [2,3], phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemurafenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone ...
CORTESI, Enrico, GIOVANNONI, SARA, Giuliana, Caprio, MEZI, Silvia, MODICA, DANIELA, URBANO, FEDERICA, VERKHOVSKAIA, SOFIA   +6 more
core   +2 more sources

Identification of a novel BRAF Thr599dup mutation in lung adenocarcinoma

Open Medicine, 2018
BRAF mutations are known as oncogenic drivers of non-small cell lung cancer (NSCLC). BRAF inhibition has demonstrated anti-tumor activity in patients with BRAF V600E mutant NSCLC. Further molecular screening for novel BRAF thr599dup mutation is warranted.
Zhang Xuefei, Li Mo, Lv Desheng, Sun Ge, Bai Yu, Tian Hui, Liu Changhong   +6 more
doaj   +1 more source

Clinicopathological relevance of BRAF and SMO mutations in Chinese patients with ameloblastoma

All Life, 2023
Ameloblastomas are benign tumors associated with recurrence and morbidity. Mutations in the V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and smoothened (SMO) genes have been identified in ameloblastomas.
Chen Ruixue, Li Hexiang, Hou Yali, Li Xiangjun, Sun Xu, Wang Jie, Zhang Xudong   +6 more
doaj   +1 more source

PIK3CA mutations in advanced cancers: characteristics and outcomes. [PDF]

, 2012
PIK3CA mutations are frequently diagnosed in diverse cancers and may predict response to PI3K/AKT/mTOR inhibitors. It remains unclear whether they are associated with other characteristics.
Falchook, Gerald S, Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S, Janku, Filip, Kurzrock, Razelle, Lee, Jack J, Luthra, Rajyalakshmi, Moulder, Stacy L, Naing, Aung, Piha-Paul, Sarina A, Stepanek, Vanda M, Tsimberidou, Apostolia M, Wheler, Jennifer J   +13 more
core   +4 more sources

Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. [PDF]

PLoS ONE, 2014
OBJECTIVE: To evaluate the association of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma (PTC).
Ah Young Park, Eun Ju Son, Jeong-Ah Kim, Ji Hyun Youk, Yun Joo Park, Cheong Soo Park, Hang Seok Chang   +6 more
doaj   +1 more source

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source